Assessment of clinical variables as predictive markers in the development and progression of colorectal cancer

References

• Bhandari A, Woodhouse M, Gupta S. Colorectal cancer is a leading cause of cancer incidence and mortality among adults younger than 50 years in the USA: a SEER-based analysis with comparison to other young-onset cancers. J Invest Med. 2017;65(2):311–315.
   PubMed Web of Science ®Google Scholar
• Wang X, Li T. Development of a 15-gene signature for predicting prognosis in advanced colorectal cancer. Bioengineered. 2020;11(1):165–174.
   PubMed Web of Science ®Google Scholar
• Shussman N, Wexner S. Colorectal polyps and polyposis syndromes. Gastroenterol Rep. 2014;2(1–15):1–15.
   Google Scholar
• Hagland HR, Berg M, Jolma IW, et al. Molecular pathways and cellular metabolism in colorectal cancer. Dig Surg. 2013;30(1):12–25.
   PubMed Web of Science ®Google Scholar
• Glei M, Latunde-Dada GO, Klinder A, et al. Iron-overload induces oxidative DNA damage in the human colon carcinoma cell line HT29 clone 19A. Mutat Res Genet Toxicol Environ Mutagen. 2002;519(1–2):151–161.
   PubMed Web of Science ®Google Scholar
• Perše M. Oxidative stress in the pathogenesis of colorectal cancer: cause or consequence? Biomed Res Int. 2013;2013:1–9.
   PubMed Web of Science ®Google Scholar
• Arthur Kaser A, Zeissig S, Blumberg RS. Inflammatory bowel disease. Annu Rev Immunol. 2010;28(1):573–621.
   PubMedGoogle Scholar
• Lee H, Herrmann A, Deng J-H, et al. Persistently activated Stat3 maintains constitutive NF-κB activity in tumors. Cancer Cell. 2009;15(4):283–293.
   PubMed Web of Science ®Google Scholar
• Tsilidis KK, Branchini C, Guallar E, et al. C‐reactive protein and colorectal cancer risk: a systematic review of prospective studies. Int J Cancer. 2008;123(5):1133–1140.
   PubMed Web of Science ®Google Scholar
• Yang B, Tang F, Zhang B, et al. Matrix metalloproteinase-9 overexpression is closely related to poor prognosis in patients with colon cancer. World J Surg Oncol. 2014;12(1):24.
   PubMedGoogle Scholar
• Haggar FA, Boushey RP. Colorectal cancer epidemiology: incidence, mortality, survival, and risk factors. Clin Colon Rectal Surg. 2009;22(4):191–197.
   PubMedGoogle Scholar
• Kakkar P, Das B, Viswanathan P A modified spectrophotometric assay of superoxide dismutase. 1984.
   Google Scholar
• Ohkawa H, Ohishi N, Yagi K. Assay for lipid peroxides in animal tissues by thiobarbituric acid reaction. Anal Biochem. 1979;95(2):351–358.
   PubMed Web of Science ®Google Scholar
• Aebi H. Catalase In: bergmeyer, editor. In:: Methods in enzymatic analysis. New York: Academic Press Inc. 1984. p. 674–684.
   Google Scholar
• Moron MS, Depierre JW, Mannervik B. Levels of glutathione, glutathione reductase and glutathione S-transferase activities in rat lung and liver. Biochim Biophys Acta. 1979;582(1):67–78.
   PubMed Web of Science ®Google Scholar
• Yang B, Tang F, Zhang B, et al. Matrix metalloproteinase-9 overexpression is closely related to poor prognosis in patients with colon cancer. World J Surg Oncol. 2014;12(1):1–6.
   PubMedGoogle Scholar
• Feelisch M, Stamler J. Methods in nitric oxide research. Wiley-Blackwell; 1996.
   Google Scholar
• Babbs CF. Free radicals and the etiology of colon cancer. Free Radic Biol Med. 1990;8(2):191–200.
   PubMed Web of Science ®Google Scholar
• Goyette P, Labbe C, Trinh TT, et al. Molecular pathogenesis of inflammatory bowel disease: genotypes, phenotypes and personalized medicine. Ann Med. 2007;39(3):177–199.
   PubMed Web of Science ®Google Scholar
• Skrzydlewska E, Sulkowski S, Koda M, et al. Lipid peroxidation and antioxidant status in colorectal cancer. World J Gastroenterol. 2005;11(3):403.
   PubMed Web of Science ®Google Scholar
• Oztürk H, Karaayvaz M, Kacmaz M, et al. Activities of the enzymes participating in purine and free-radical metabolism in cancerous human colorectal tissues. Cancer biochem biophy. 1998;16(1–2):157–168.
   PubMedGoogle Scholar
• Ma Y, Zhang L, Rong S, et al. Relation between gastric cancer and protein oxidation, DNA damage, and lipid peroxidation. Oxid Med Cell Longev. 2013;2013:2013.
   Web of Science ®Google Scholar
• Skrzycki M, Majewska M, Czeczot H. Superoxide dismutase mRNA and protein level in human colorectal cancer. Open Life Sci. 2010;5(5):590–599.
   Google Scholar
• Barrett CW, Ning W, Chen X, et al. Tumor suppressor function of the plasma glutathione peroxidase gpx3 in colitis-associated carcinoma. Cancer Res. 2013;73(3):1245–1255.
   PubMed Web of Science ®Google Scholar
• Janakiram NB, Rao CV The role of inflammation in colon cancer. Inflammation and cancer. 2014:25–52
   Google Scholar
• Harris TB, Ferrucci L, Tracy RP, et al. Associations of elevated interleukin-6 and C-reactive protein levels with mortality in the elderly. Am J Med. 1999;106(5):506–512.
   PubMed Web of Science ®Google Scholar
• Kakourou A, Koutsioumpa C, Lopez DS, et al. Interleukin-6 and risk of colorectal cancer: results from the CLUE II cohort and a meta-analysis of prospective studies. Cancer Causes Control. 2015;26(10):1449–1460.
   PubMed Web of Science ®Google Scholar
• Balkwill F, Mantovani A. Inflammation and cancer: back to Virchow? Lancet. 2001;357(9255):539–545.
   PubMed Web of Science ®Google Scholar
• Burke F, Relf M, Negus R, et al. A cytokine profile of normal and malignant ovary. Cytokine. 1996;8(7):578–585.
   PubMed Web of Science ®Google Scholar
• De Vita F, Orditura M, Lieto E, et al. Elevated perioperative serum vascular endothelial growth factor levels in patients with colon carcinoma. Cancer. 2004;100(2):270–278.
   PubMed Web of Science ®Google Scholar
• Knüpfer H, Preiss R. Serum interleukin-6 levels in colorectal cancer patients—a summary of published results. Int J Colorectal Dis. 2010;25(2):135–140.
   PubMed Web of Science ®Google Scholar
• Xia W, Chen W, Zhang Z, et al. Prognostic value, clinicopathologic features and diagnostic accuracy of interleukin-8 in colorectal cancer: a meta-analysis. PloS One. 2015;10(4):e0123484. .
   PubMed Web of Science ®Google Scholar
• Gunawardene A, Dennett E, Larsen P. Prognostic value of multiple cytokine analysis in colorectal cancer: a systematic review. J Gastrointest Oncol. 2019;10(1):134.
   PubMed Web of Science ®Google Scholar
• Lane D, Matte I, Rancourt C, et al. Prognostic significance of IL-6 and IL-8 ascites levels in ovarian cancer patients. BMC Cancer. 2011;11(1):1–6.
   PubMedGoogle Scholar
• Waldner MJ, Foersch S, Neurath MF. Interleukin-6-a key regulator of colorectal cancer development. Int J Biol Sci. 2012;8(9):1248.
   PubMed Web of Science ®Google Scholar
• Shiga K, Hara M, Nagasaki T, et al. Preoperative serum interleukin-6 is a potential prognostic factor for colorectal cancer, including stage II patients. Gastroenterol Res Pract. 2016;2016:2016.
   Web of Science ®Google Scholar
• Wang Y, Niu XL, Qu Y, et al. Autocrine production of interleukin-6 confers cisplatin and paclitaxel resistance in ovarian cancer cells. Cancer Lett. 2010;295(1):110–123.
   PubMed Web of Science ®Google Scholar
• Cohen S, Bruchim I, Graiver D, et al. Platinum-resistance in ovarian cancer cells is mediated by IL-6 secretion via the increased expression of its target cIAP-2. J Mol Med. 2013;91(3):357–368.
   PubMed Web of Science ®Google Scholar
• Banday MZ, Balkhi HM, Sameer AS, et al. Strong association of interleukin-6− 174G/C promoter single nucleotide polymorphism with a decreased risk of colorectal cancer in ethnic Kashmiri population: a case control study. Tumor Biol. 2017;39(3):1010428317695940.
   Google Scholar
• Hefler LA, Grimm C, Ackermann S, et al. An interleukin-6 gene promoter polymorphism influences the biological phenotype of ovarian cancer. Cancer Res. 2003;63(12):3066–3068.
   PubMed Web of Science ®Google Scholar
• Ning Y, Lenz H-J. Targeting IL-8 in colorectal cancer. Expert Opin Ther Targets. 2012;16(5):491–497.
   PubMed Web of Science ®Google Scholar
• Terada H, Urano T, Konno H. Association of interleukin-8 and plasminogen activator system in the progression of colorectal cancer. Eur Surg Res. 2005;37(3):166–172.
   PubMed Web of Science ®Google Scholar
• Waugh DJ, Wilson C. The interleukin-8 pathway in cancer. Clin Cancer Res. 2008;14(21):6735–6741.
   PubMed Web of Science ®Google Scholar
• Lurje G, Husain H, Power D, et al. Genetic variations in angiogenesis pathway genes associated with clinical outcome in localized gastric adenocarcinoma. Ann Oncol. 2010;21(1):78–86.
   PubMed Web of Science ®Google Scholar
• Uslu R, Sanli U, Dikmen Y, et al. Predictive value of serum interleukin-8 levels in ovarian cancer patients treated with paclitaxel-containing regimens. Int J Gynecologic Cancer. 2005;15(2):2.
   Web of Science ®Google Scholar
• Hull J, Thomson A, Kwiatkowski D. Association of respiratory syncytial virus bronchiolitis with the interleukin 8 gene region in UK families. Thorax. 2000;55(12):1023–1027.
   PubMed Web of Science ®Google Scholar
• Lee W-P, Tai D-I, Lan K-H, et al. The− 251T allele of the interleukin-8 promoter is associated with increased risk of gastric carcinoma featuring diffuse-type histopathology in Chinese population. Clin Cancer Res. 2005;11(18):6431–6441.
   PubMed Web of Science ®Google Scholar
• Taguchi A, Ohmiya N, Shirai K, et al. Interleukin-8 promoter polymorphism increases the risk of atrophic gastritis and gastric cancer in Japan. Cancer Epidemiol Prev Biomarkers. 2005;14(11):2487–2493.
   PubMed Web of Science ®Google Scholar
• Koehne C, Dubois R. COX-2 inhibition and colorectal cancer. In: Seminars in oncology. 31. pp.12-21. WB Saunders; 2004.
   Google Scholar
• Jones MK, Wang H, Peskar BM, et al. Inhibition of angiogenesis by nonsteroidal anti-inflammatory drugs: insight into mechanisms and implications for cancer growth and ulcer healing. Nat Med. 1999;5(12):1418–1423.
   PubMed Web of Science ®Google Scholar
• Tessner TG, Muhale F, Riehl TE, et al. Prostaglandin E 2 reduces radiation-induced epithelial apoptosis through a mechanism involving AKT activation and bax translocation. J Clin Invest. 2004;114(11):1676–1685.
   PubMed Web of Science ®Google Scholar
• Pozzi A, Yan X, Macias-Perez I, et al. Colon carcinoma cell growth is associated with prostaglandin E2/EP4 receptor-evoked ERK activation. J Biol Chem. 2004;279(28):29797–29804.
   PubMed Web of Science ®Google Scholar
• Eberhart CE, Coffey RJ, Radhika A, et al. Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas. Gastroenterology. 1994;107(4):1183–1188.
   PubMed Web of Science ®Google Scholar
• Zhang J, Mao T, Wang S, et al. Interleukin-35 expression is associated with colon cancer progression. Oncotarget. 2017;8(42):71563.
   PubMedGoogle Scholar
• Morin PJ, Sparks AB, Korinek V, et al. Activation of β-catenin-Tcf signaling in colon cancer by mutations in β-catenin or APC. Science. 1997;275(5307):1787–1790.
   PubMed Web of Science ®Google Scholar
• Said AH, Raufman J-P XG, Xie G. The role of matrix metalloproteinases in colorectal cancer. Cancers (Basel). 2014;6(1):366–375.
   PubMed Web of Science ®Google Scholar
• Kanda S, Kuzuya M, Ramos MA, et al. Matrix metalloproteinase and αvβ3 Integrin–dependent vascular smooth muscle cell invasion through a Type I collagen lattice. Arterioscler Thromb Vasc Biol. 2000;20(4):998–1005.
   PubMed Web of Science ®Google Scholar
• Munshi H, Stack M. Reciprocal interactions between adhesion receptor signaling and MMP regulation. Cancer Metast Rev. 2006;25(1):45–56.
   PubMed Web of Science ®Google Scholar
• Kryczka J, Stasiak M, Dziki L, et al. Matrix metalloproteinase-2 cleavage of the β1 integrin ectodomain facilitates colon cancer cell motility. J Biol Chem. 2012;287(43):36556–36566.
   PubMed Web of Science ®Google Scholar
• Loesch M, Zhi H-Y, Hou S-W, et al. p38γ MAPK cooperates with c-Jun in trans-activating matrix metalloproteinase 9. J Biol Chem. 2010;285(20):15149–15158.
   PubMed Web of Science ®Google Scholar
• Zhang B, Halder SK, Kashikar ND, et al. Antimetastatic role of Smad4 signaling in colorectal cancer. Gastroenterology. 2010;138(3):969–80. e3.
   PubMed Web of Science ®Google Scholar
• Papageorgis P, Cheng K, Ozturk S, et al. Smad4 inactivation promotes malignancy and drug resistance of colon cancer. Cancer Res. 2011;71(3):998–1008.
   PubMed Web of Science ®Google Scholar
• Langenskiöld M, Holmdahl L, Falk P, et al. Increased plasma MMP-2 protein expression in lymph node-positive patients with colorectal cancer. Int J Colorectal Dis. 2005;20(3):245–252.
   PubMed Web of Science ®Google Scholar
• Sena P, Mariani F, Marzona L, et al. Matrix metalloproteinases 15 and 19 are stromal regulators of colorectal cancer development from the early stages. Int J Oncol. 2012;41(1):260–266.
   PubMed Web of Science ®Google Scholar
• Xu C-J XF. MMP-11 and VEGF-C expression correlate with clinical features of colorectal adenocarcinoma. Int J Clin Exp Med. 2014;7(9):2883.
   PubMed Web of Science ®Google Scholar
• Nerpin E, Helmersson-Karlqvist J, Risérus U, et al. Inflammation, oxidative stress, glomerular filtration rate, and albuminuria in elderly men: a cross-sectional study. BMC Res Notes. 2012;5(1):537.
   PubMedGoogle Scholar